한글목차

세계 약물유전체학 시장 규모는 2024년 86억 달러에 달했습니다. 향후 IMARC Group은 이 시장이 2033년까지 170억 달러에 달해 2025년부터 2033년까지 7.55%의 연평균 성장률(CAGR)을 기록할 것으로 예상하고 있습니다.

약물유전체학은 특정 약물에 대한 인간 유전자의 유전적 변이를 연구하는 학문입니다. 약리학과 유전체학의 원리를 활용하여 개인의 유전자 구성에 맞는 효과적이고 안전한 약물을 개발합니다. 중합효소 연쇄 반응(PCR), 마이크로어레이, 데옥시리보핵산(DNA) 시퀀싱, 질량분석, 전기영동 등 다양한 기술을 활용합니다. 약물유전체학에서 시행되는 유전자 검사는 특정 질병에 대한 감수성이나 새로 개발된 약물의 효능을 판단하는 데 도움이 됩니다. 약물유전체학은 심혈관, 알츠하이머, 암, 인간면역결핍바이러스 및 후천성면역결핍증후군(HIV/AIDS), 천식 등 다양한 질환의 치료에도 폭넓게 활용되고 있습니다.

약물유전체학 시장 동향:

세계 제약 산업의 괄목할만한 성장은 시장 전망을 밝게 하는 중요한 요인 중 하나입니다. 또한, 의약품의 안전성을 높인 정밀 의약품에 대한 수요 증가가 시장 성장을 견인하고 있습니다. 만성 생활습관병이 증가함에 따라 부작용을 최소화하고 효능을 높인 표적 약물요법의 채택이 확대되고 있습니다. 이에 따라 약물유전체학은 암 치료에 널리 사용되어 화학요법제나 표적 면역생물학적 제제의 잠재적인 약물 반응, 내성, 효능, 독성을 예측하는 데에도 활용되고 있으며, 이 또한 시장 성장에 기여하고 있습니다. 또한, 약리유전체 바이오마커 표지 솔루션 개발 등 다양한 기술 발전도 성장을 촉진하는 요인으로 작용하고 있습니다. 이는 체내에서 피할 수 있는 약물 부작용(ADR)의 위험을 최소화하고 임상 결과를 개선하는 데 도움이 됩니다. 그 외의 요인으로는 광범위한 연구개발 활동, 의료 인프라의 대폭적인 개선 등이 시장 성장을 견인할 것으로 예상됩니다.

본 보고서에서 다루는 주요 질문

• 약물유전체학 시장 규모는?
• 약물유전체학 시장의 향후 전망은?
• 약물유전체학 시장을 이끄는 주요 요인은 무엇인가?
• 세계 약물유전체학 시장의 주요 기업은?

목차

제1장 서문

제2장 조사 범위와 조사 방법

• 조사 목적
• 이해관계자
• 데이터 소스
  • 1차 정보
  • 2차 정보
• 시장 추정
  • 상향식 접근
  • 하향식 접근
• 조사 방법

제3장 주요 요약

제4장 소개

제5장 세계의 약물유전체학 시장

• 시장 개요
• 시장 실적
• COVID-19의 영향
• 시장 예측

제6장 시장 내역 : 기술별

• 중합효소 연쇄 반응(PCR)
• 마이크로어레이
• DNA 시퀀싱
• 질량 분석
• 전기영동
• 기타

제7장 시장 내역 : 용도별

• 종양
• 감염증
• 심혈관질환
• 신경질환
• 정신의학
• 통증 관리
• 기타

제8장 시장 내역 : 최종사용자별

• 병원·진료소
• 학술·연구기관

제9장 시장 내역 : 지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 인도네시아
  • 기타
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 러시아
  • 기타
• 라틴아메리카
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카

제10장 SWOT 분석

제11장 밸류체인 분석

제12장 Porter's Five Forces 분석

제13장 가격 분석

제14장 경쟁 구도

• 시장 구조
• 주요 기업
• 주요 기업 개요
  • Abbott Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Becton Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Illumina Inc.
  • Johnson & Johnson
  • Merck KGaA
  • Myriad Genetics Inc.
  • Qiagen N.V.
  • Thermo Fisher Scientific Inc

영문목차

The global pharmacogenomics market size reached USD 8.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 17.0 Billion by 2033, exhibiting a growth rate (CAGR) of 7.55% during 2025-2033.

Pharmacogenomics is the study of inherited variations in human genes in response to specific drugs. It utilizes the principles of pharmacology and genomics to develop effective and safe medications that are customized to the genetic makeup of an individual. It involves the use of various technologies, such as polymerase chain reaction (PCR), microarray, deoxyribonucleic acid (DNA) sequencing, mass spectrometry and electrophoresis. The genetic tests performed in pharmacogenomics aid in determining the susceptibility to certain diseases and efficacy of the newly developed drugs. Pharmacogenomics is also widely used in the treatment of various diseases, such as cardiovascular, Alzheimer's, cancer, human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS) and asthma.

Pharmacogenomics Market Trends:

Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing demand for precision medicines with enhanced drug safety is providing a thrust to the growth of the market. With the increasing prevalence of chronic lifestyle diseases, there is widespread adoption of targeted drug therapies with minimal side effects and improved efficacy. In line with this, pharmacogenomics is also extensively used for cancer treatments and anticipating the possible drug responses, resistance, efficacy and toxicity of the chemotherapeutic and targeted immune biologic agents, which is also contributing to the market growth. Additionally, various technological advancements, such as the development of pharmacogenomic biomarker labeling solutions, are acting as other growth-inducing factors. They aid in minimizing the risks of avoidable adverse drug reactions (ADRs) in the body and improve clinical outcomes. Other factors, including extensive research and development (R&D) activities, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Technology:

• Polymerase Chain Reaction
• Microarray
• DNA Sequencing
• Mass Spectrometry
• Electrophoresis
• Others

Breakup by Application:

• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Neurological Diseases
• Psychiatry
• Pain Management
• Others

Breakup by End User:

• Hospitals and Clinics
• Academic and Research Institutes

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Bayer AG, Becton Dickinson and Company, Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Illumina Inc., Johnson & Johnson, Merck KGaA, Myriad Genetics Inc., Qiagen N.V. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

• 1.How big is the pharmacogenomics market?
• 2.What is the future outlook of pharmacogenomics market?
• 3.What are the key factors driving the pharmacogenomics market?
• 4.Which are the leading companies in the global pharmacogenomics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Pharmacogenomics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Technology

• 6.1 Polymerase Chain Reaction
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Microarray
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 DNA Sequencing
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Mass Spectrometry
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Electrophoresis
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Others
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Application

• 7.1 Oncology
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Infectious Diseases
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Cardiovascular Diseases
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Neurological Diseases
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Psychiatry
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Pain Management
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Others
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals and Clinics
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Academic and Research Institutes
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 AstraZeneca plc
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Bayer AG
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Becton Dickinson and Company
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Bio-Rad Laboratories Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 F. Hoffmann-La Roche AG
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 SWOT Analysis
  • 14.3.7 GlaxoSmithKline plc
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Illumina Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Johnson & Johnson
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Merck KGaA
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Myriad Genetics Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Qiagen N.V.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis
  • 14.3.13 Thermo Fisher Scientific Inc
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio
    • 14.3.13.3 Financials
    • 14.3.13.4 SWOT Analysis